Author: aveak

Reunion Neuroscience Presents Full Data from RECONNECT Phase 2 Clinical Trial of RE104 for the Treatment of Postpartum Depression (PPD) at ACNP Annual Meeting

Reunion Neuroscience, Inc., today announced the full results of RECONNECT, a Phase 2 clinical trial evaluating RE104 in adult female patients with moderate-to-severe PPD. The data were presented at the American College of Neuropsychopharmacology (ACNP) Annual Meeting and the poster presentation is now available on the Reunion website...

20 January, 2026

Reunion Neuroscience Announces Program Updates and Highlights Anticipated 2026 Milestones

Reunion Neuroscience, Inc., a clinical-stage biopharmaceutical company committed to revolutionizing the treatment of underserved mental health disorders through the advancement of next-generation psychedelic-inspired therapeutic solutions, today announced program updates and anticipated 2026 milestones. ...

12 January, 2026

Reunion Neuroscience Announces First Patient Dosed in REKINDLE Phase 2 Clinical Trial of RE104 for the Treatment of Adjustment Disorder (AjD) in Cancer and Other Medical Illnesses

Reunion Neuroscience Inc. today announced the closing of its Series A financing. Under the amended terms of the Series A financing, because certain efficacy parameters were met including achieving a statistically significant and clinically meaningful outcome for the RECONNECT study, the final tranche of the financing increased from $21 to...

30 September, 2025

Reunion Neuroscience Announces Final Closing of its Series A Financing and Plans to Advance RE104 into Clinical Development for the Treatment of Generalized Anxiety Disorder (GAD)

Reunion Neuroscience Inc. today announced the closing of its Series A financing. Under the amended terms of the Series A financing, because certain efficacy parameters were met including achieving a statistically significant and clinically meaningful outcome for the RECONNECT study, the final tranche of the financing increased from $21 to...

16 September, 2025

Reunion Neuroscience Announces Positive Topline Results from RECONNECT Phase 2 Clinical Trial of RE104 for the Treatment of Postpartum Depression (PPD)

Reunion Neuroscience Inc. today announced positive topline results from its RECONNECT Phase 2 clinical trial evaluating RE104 in adult female patients with moderate-to-severe postpartum depression (PPD). ...

18 August, 2025

Reunion Neuroscience Announces Publication of RE104 Phase 1 Data in The Journal of Clinical Psychopharmacology

Reunion Neuroscience Inc. today announced the publication of  a manuscript entitled “Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneous RE104: A Double-Blind, Randomized, Single Ascending Dose Placebo-Controlled Study,” describing the results of a Phase 1 study of RE104 in the peer-reviewed Journal of Clinical Psychopharmacology....

22 July, 2025

Reunion Neuroscience Announces Last Patient Dosed in RECONNECT Phase 2 Clinical Trial of RE104 for the Treatment of Postpartum Depression (PPD)

Reunion Neuroscience, Inc. today announced the completion of patient enrollment and the last patient dosed in RECONNECT, a Phase 2 clinical trial evaluating RE104 in adult female patients with moderate-to-severe postpartum depression (PPD). ...

19 May, 2025

Reunion Neuroscience Presents REKINDLE, a Phase 2 Clinical Trial Evaluating RE104 for the Treatment of Adjustment Disorder (AjD) in Cancer and Other Medical Illnesses at the Anxiety & Depression Association of America (ADAA) 2025 Conference

Reunion Neuroscience Inc., a clinical-stage biopharmaceutical company committed to revolutionizing the treatment of underserved mental health disorders through the advancement of next-generation psychedelic-inspired therapeutic solutions, presented the study design for the REKINDLE Phase 2 clinical trial, which will evaluate the safety and efficacy of RE104 for the treatment of adjustment...

06 April, 2025

Reunion Neuroscience Announces Participation in Premiere Maternal Mental Health Event

Reunion Neuroscience Inc., a clinical-stage biopharmaceutical company committed to revolutionizing the treatment of underserved mental health disorders through the advancement of next-generation psychedelic-inspired therapeutic solutions, today announced its participation in  The Policy Center for Maternal Mental Health’s 2025 Maternal Mental Health (MMH) FORUM, taking place March 18-19, 2025....

04 March, 2025

Reunion Neuroscience Announces Program Updates and Highlights Anticipated 2025 Milestones

Reunion Neuroscience Inc. today announced program updates and anticipated 2025 milestones. The Company also announced that Greg Mayes, President and Chief Executive Officer, will present a corporate overview and participate in a panel discussion entitled “Future of Psychedelics” at the 8th Annual Neuroscience Innovation Forum, taking place January 12, 2025...

06 January, 2025